Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.47 |
| ▸ | EED | O75530 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420658 | 0.85 | MAOB (0.56) | MAOBKCNH2SCN3ANR4A2SLC6A2 | |
| SCHEMBL13107011 | 0.85 | SLC6A2 (0.53) | EEDSLC6A2SLC6A4SLC6A3MAP2K1 | |
| SCHEMBL7327361 | 0.85 | SLC6A2 (0.53) | MAOBEEDSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7328352 | 0.84 | SLC6A2 (0.52) | MAOBEEDSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL16823666 | 0.84 | SLC6A2 (0.52) | EEDSLC6A2SLC6A4SLC6A3MAP2K1 | |
| SCHEMBL3163776 | 0.82 | MAP2K1 (0.53) | SLC6A2SLC6A4SLC6A3MAP2K1 | |
| Hydrochloric Acid SCHEMBL1768943 | 0.81 | MAP2K1 (0.52) | SLC6A2SLC6A4SLC6A3MAP2K1 | |
| SCHEMBL3160166 | 0.78 | EED (0.64) | EEDSLC6A2SLC6A3 | |
| SCHEMBL7327587 | 0.77 | LTA4H (0.65) | EEDSLC6A2SLC6A4SLC6A3MAP2K1 | |
| SCHEMBL6293801 | 0.77 | MAP2K1 (0.51) | EEDSLC6A2SLC6A4SLC6A3MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MAOB 222/4885KCNH2 640/4885SCN3A 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.